Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...
CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is an advanced technology developed in 2012 that can be used to edit genes. It can be used to find specific DNA sequences inside ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
Crispr Therapeutics treibt die Kommerzialisierung seiner ersten Gentherapie Casgevy massiv voran. Während die Behandlungsstarts im Vergleich zum Vorjahr fast verdreifacht wurden, bereitet das Unterneh ...
CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...
The coronavirus disease 2019 (COVID-19) pandemic was one of the most serious public health calamities in the last decade, causing global morbidity and mortality in the millions. The emergence of ...
Rodolphe Barrangou, PhD, is the T. R. Klaenhammer Distinguished Professor at North Carolina State University, where he leads the CRISPR Lab. Rodolphe spent nine years at Danisco and DuPont, where he ...
Last August, KJ Muldoon was born with a potentially fatal genetic disorder. Just six months later, he received a Crispr treatment designed just for him. Muldoon has a rare disorder known as CPS1 ...
Der Rat der EU-Aussenminister hat am Dienstag die neuen EU-Regelungen zur Neuen Gentechnik (NGT) in der Pflanzenzüchtung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results